Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant.
Immune thrombocytopenia is well recognized post both allogeneic and autologous transplantation. The diagnosis can be difficult as there are generally several complicating features, including delayed marrow recovery and the use of multiple therapies. Treatment can be difficult and conventional approaches are often unsuccessful. We describe a case of presumed immune thrombocytopenia post autologous stem cell transplantation, who appeared to respond to the monoclonal B-cell antibody, rituxmab, which is being increasingly recognized as a therapeutic option in a variety of autoimmune disorders.
Price
Samantha
S
Hematology/Oncology, West Virginia University Hospitals, Medical Center Drive, PO Box 8045, Morgantown, 26506-9162, USA.
Cumpston
Aaron
A
Altaha
Ramin
R
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy*; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000009:adverse effects; D014182:Transplantation, Autologous
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab